Clinical trial

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

NCT05342558

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Fluticasone Furoate/Vilanterol 100/25 mcgs Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Umeclidinium/Vilanterol 62.5/25 mcgs Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-09-19

PhasePHASE4

Conditions

COPDverified · MONDO: chronic obstructive pulmonary disease

Interventions

Fluticasone Furoate/Vilanterol 100/25 mcgsDRUG

Umeclidinium/Vilanterol 62.5/25 mcgsDRUG

Sponsors & collaborators

National Institute of Respiratory Diseases, Mexicolead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05342558 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.